Sep 29, 2024 Leave a message

Sulbactam Sodium: Beta-Lactamase Inhibitor API, Properties and Uses

What Is Sulbactam Sodium?

Sulbactam sodium is the sodium salt form of sulbactam, a semisynthetic beta-lactam compound that works as an irreversible, competitive beta-lactamase inhibitor. The molecule carries the characteristic four-membered beta-lactam ring and binds covalently at or near the active site of beta-lactamase enzymes, permanently blocking their catalytic activity and preventing the enzymatic destruction of co-administered beta-lactam antibiotics. Used alone, sulbactam sodium shows only weak antibacterial action; its commercial and clinical value comes from shielding partner antibiotics such as ampicillin from penicillinase-producing and beta-lactamase-producing organisms, which lowers the turnover rate of the sensitive antibiotic and broadens its spectrum of activity.

Identity and Typical Supply Specification

Sulbactam sodium is handled as a pharmaceutical-grade active pharmaceutical ingredient (API) in powder form. Buyers normally qualify it against a pharmacopoeial monograph and an agreed certificate of analysis. The table below summarises the identity data and the parameters usually written into a purchase specification.

Parameter Value / Typical requirement
Chemical name Sodium (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide
Common name Sulbactam sodium
CAS number 69388-84-7 (free acid form: 68373-14-8)
Molecular formula C8H10NNaO5S
Molar mass Approximately 255.2 g/mol
Appearance White to off-white crystalline powder
Assay (anhydrous basis) 98.0-102.0% as required by the pharmacopoeial monograph
Solubility Freely soluble in water; practically insoluble in non-polar organic solvents
Storage Sealed, light-resistant container; protect from moisture and heat
Standard packaging 25 kg fibre drum with double polyethylene liner, or as agreed

Mechanism of Action

Beta-lactam antibiotics are inactivated when bacterial beta-lactamase enzymes hydrolyse the beta-lactam ring before the drug can reach its penicillin-binding protein targets. Sulbactam sodium competes with the antibiotic for the enzyme active site and, once bound, undergoes a rearrangement that leaves the enzyme irreversibly inhibited. Because the inhibitor itself is consumed in the reaction, its protective effect is concentration-dependent and lasts until new enzyme is synthesised by the organism.

In addition to this inhibitor role, sulbactam retains intrinsic activity against a limited group of organisms, most notably Acinetobacter species, where it binds penicillin-binding proteins directly. This dual behaviour explains why sulbactam-containing combinations are still evaluated for multidrug-resistant Acinetobacter infections, frequently together with a second beta-lactam partner.

Pharmacokinetics

Sulbactam sodium is poorly absorbed after oral administration, so it is given by intramuscular or intravenous injection in clinical use. The values below reflect published pharmacokinetic data for single doses in healthy adults.

Route and dose Mean peak serum concentration Time to peak
Intramuscular 0.5 g About 13 microgram/mL 0.5 hour
Intramuscular 1.0 g About 28 microgram/mL 0.5 hour
Intravenous infusion 0.5 g (30 minutes) About 20 microgram/mL End of infusion
Intravenous infusion 1.0 g (30 minutes) About 43 microgram/mL End of infusion

Elimination half-life: approximately 1 hour.

Co-administration with ampicillin produces little change in sulbactam serum concentrations.

Distribution: penetrates female genital tissue, intestinal mucosa, peritoneal fluid and interstitial fluid; crosses the placental barrier and is detectable in breast milk.

Cerebrospinal fluid: after intravenous dosing of 1 g sulbactam sodium with 0.8-2 g ampicillin in patients with bacterial meningitis, sulbactam concentrations of 0.5-12 microgram/mL were measured 1-4 hours after dosing.

Excretion: predominantly renal. Roughly 70% of a dose is recovered unchanged in urine within 6 hours and about 85% within 24 hours, so renal function directly affects exposure.

Combination Products and Applications

Commercial products pair sulbactam sodium with a beta-lactam partner in a fixed ratio, most commonly ampicillin and sulbactam or cefoperazone and sulbactam. The combinations are indicated for bacterial infections including tonsillitis, sinusitis, otitis media, lower and upper respiratory tract infections, urinary tract infections, intra-abdominal and gynaecological infections, skin and soft tissue infections such as boils, abscesses, cellulitis and wound infection, bone and joint infection, and infections of the oral cavity. Selection between partners is normally based on local resistance surveillance, culture and susceptibility results, and renal function.

Quality Control, Handling and Sourcing Notes

Sulbactam sodium is moisture-sensitive and hydrolyses under humid or alkaline conditions, so release testing and stability studies focus on assay, related substances, water content, clarity and colour of solution, and residual solvents. Beta-lactam APIs manufactured for regulated markets are produced under ICH Q7 good manufacturing practice, with residual solvent limits set by ICH Q3C and elemental impurity limits by ICH Q3D. For sourcing, buyers should request the current certificate of analysis, the drug master file or equivalent regulatory dossier reference, a stability summary, and confirmation of the packaging and cold-chain or humidity-control arrangements used for transport.

FAQ

Q: What is sulbactam sodium used for?
It is a beta-lactamase inhibitor used in fixed combinations with penicillins or cephalosporins to restore and broaden their activity against beta-lactamase-producing bacteria, and it also has intrinsic activity against Acinetobacter species.

Q: Is sulbactam sodium an antibiotic on its own?
It has only weak antibacterial activity when used alone. Its main function is to protect a partner beta-lactam antibiotic from enzymatic hydrolysis rather than to kill bacteria directly.

Q: What is the CAS number of sulbactam sodium?
Sulbactam sodium is registered under CAS 69388-84-7; the corresponding free acid, sulbactam, is CAS 68373-14-8.

Q: Can sulbactam sodium be given orally?
No. Absorption after oral administration is poor, so the API is formulated for intramuscular or intravenous administration.

Q: What is the elimination half-life of sulbactam?
The half-life is approximately 1 hour, and the drug is cleared mainly by the kidneys, with about 85% of a dose excreted in urine within 24 hours.

Q: How should sulbactam sodium be stored?
Keep it in a sealed, light-resistant container protected from moisture and excessive heat, and validate the storage and transport conditions as part of the stability programme.

Send Inquiry

whatsapp

Phone

E-mail

Inquiry